Literature DB >> 27377929

Colonization of CF patients' upper airways with S. aureus contributes more decisively to upper airway inflammation than P. aeruginosa.

Wibke Katharina Janhsen1, Christin Arnold1, Julia Hentschel1,2, Thomas Lehmann3, Wolfgang Pfister4, Michael Baier4, Klas Böer5, Kerstin Hünniger6,7, Oliver Kurzai6,7, Uta-Christina Hipler8, Jochen Georg Mainz9.   

Abstract

In cystic fibrosis (CF) patients' airways, inflammatory processes decisively contribute to remodeling and pulmonary destruction. The aims of this study were to compare upper airway (UAW) inflammation in the context of Staphylococcus aureus and Pseudomonas aeruginosa colonization in a longitudinal setting, and to examine further factors influencing UAW inflammation. Therefore, we analyzed soluble inflammatory mediators in noninvasively obtained nasal lavage (NL) of CF patients together with microbiology, medication, and relevant clinical parameters. NL, applying 10 mL of isotonic saline per nostril, was serially performed in 74 CF patients (326 samples). Concentrations of the inflammatory mediators' interleukin (IL)-1β, IL-6, IL-8, matrix metalloproteinase (MMP)-9, and its anti-protease TIMP-1 were quantified by bead-based multiplexed assay, neutrophil elastase (NE) via ELISA. Culture-based microbiology of the upper and lower airways (LAW), as well as serological and clinical findings, were compiled. Our results indicate that UAW colonization with S. aureus significantly impacts the concentration of all measured inflammatory mediators in NL fluid except TIMP-1, whereas these effects were not significant for P. aeruginosa. Patients with S. aureus colonization of both the UAW and LAW showed significantly increased concentrations of IL-1β, IL-6, IL-8, MMP-9, and slightly elevated concentrations of NE in NL fluid compared to non-colonized patients. This work elaborates a survey on S. aureus' virulence factors that may contribute to this underestimated pathology. Serial assessment of epithelial lining fluid by NL reveals that colonization of the UAW with S. aureus contributes more to CF airway inflammatory processes than hitherto expected.

Entities:  

Keywords:  Cystic fibrosis; Inflammation; Nasal lavage; Staphylococcus aureus

Mesh:

Substances:

Year:  2016        PMID: 27377929     DOI: 10.1007/s00430-016-0463-0

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  71 in total

1.  Staphylococcus aureus protein A induces airway epithelial inflammatory responses by activating TNFR1.

Authors:  Marisa I Gómez; Aram Lee; Bharat Reddy; Amanda Muir; Grace Soong; Allyson Pitt; Ambrose Cheung; Alice Prince
Journal:  Nat Med       Date:  2004-07-11       Impact factor: 53.440

Review 2.  Adhesion, invasion and evasion: the many functions of the surface proteins of Staphylococcus aureus.

Authors:  Timothy J Foster; Joan A Geoghegan; Vannakambadi K Ganesh; Magnus Höök
Journal:  Nat Rev Microbiol       Date:  2014-01       Impact factor: 60.633

3.  Staphylococcus aureus increases cytokine and matrix metalloproteinase expression in nasal mucosae of patients with chronic rhinosinusitis and nasal polyps.

Authors:  Jong Hwan Wang; Hyun Ja Kwon; Yong Ju Jang
Journal:  Am J Rhinol Allergy       Date:  2010-10-19       Impact factor: 2.467

4.  EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists.

Authors:  Wytske J Fokkens; Valerie J Lund; Joachim Mullol; Claus Bachert; Isam Alobid; Fuad Baroody; Noam Cohen; Anders Cervin; Richard Douglas; Philippe Gevaert; Christos Georgalas; Herman Goossens; Richard Harvey; Peter Hellings; Claire Hopkins; Nick Jones; Guy Joos; Livije Kalogjera; Bob Kern; Marek Kowalski; David Price; Herbert Riechelmann; Rodney Schlosser; Brent Senior; Mike Thomas; Elina Toskala; Richard Voegels; De Yun Wang; Peter John Wormald
Journal:  Rhinology       Date:  2012-03       Impact factor: 3.681

Review 5.  Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung.

Authors:  Michael Hogardt; Jürgen Heesemann
Journal:  Int J Med Microbiol       Date:  2010-10-12       Impact factor: 3.473

6.  Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis.

Authors:  Scott D Sagel; Ronald L Gibson; Julia Emerson; Sharon McNamara; Jane L Burns; Jeffrey S Wagener; Bonnie W Ramsey
Journal:  J Pediatr       Date:  2008-09-25       Impact factor: 4.406

7.  P. aeruginosa in the paranasal sinuses and transplanted lungs have similar adaptive mutations as isolates from chronically infected CF lungs.

Authors:  Oana Ciofu; Helle Krogh Johansen; Kasper Aanaes; Tina Wassermann; Morten Alhede; Christian von Buchwald; Niels Høiby
Journal:  J Cyst Fibros       Date:  2013-03-09       Impact factor: 5.482

Review 8.  Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications.

Authors:  Malena Cohen-Cymberknoh; Eitan Kerem; Thomas Ferkol; Arnon Elizur
Journal:  Thorax       Date:  2013-05-23       Impact factor: 9.139

9.  Clinical outcomes associated with Staphylococcus aureus and Pseudomonas aeruginosa airway infections in adult cystic fibrosis patients.

Authors:  Heather G Ahlgren; Andrea Benedetti; Jennifer S Landry; Joanie Bernier; Elias Matouk; Danuta Radzioch; Larry C Lands; Simon Rousseau; Dao Nguyen
Journal:  BMC Pulm Med       Date:  2015-06-21       Impact factor: 3.317

10.  Depletion of neutrophil extracellular traps in vivo results in hypersusceptibility to polymicrobial sepsis in mice.

Authors:  Wei Meng; Adnana Paunel-Görgülü; Sascha Flohé; Almuth Hoffmann; Ingo Witte; Colin MacKenzie; Stephan E Baldus; Joachim Windolf; Tim T Lögters
Journal:  Crit Care       Date:  2012-07-26       Impact factor: 9.097

View more
  1 in total

1.  The SaeRS Two-Component System Controls Survival of Staphylococcus aureus in Human Blood through Regulation of Coagulase.

Authors:  Haiyong Guo; Jeffrey W Hall; Junshu Yang; Yinduo Ji
Journal:  Front Cell Infect Microbiol       Date:  2017-05-29       Impact factor: 5.293

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.